Acetaminophen is an analgesic and antipyretic indicated for mild to moderate pain and fever. We supply it to US manufacturers of tablets, capsules, oral suspension and injection.
Data from PubChem (CID 1983) and FDA’s substance registry
CAS number
103-90-2
Molecular formula
C8H9NO2
Molecular weight
151.2g/mol
FDA UNII
IUPAC name
N-(4-hydroxyphenyl)acetamide
InChIKey
RZVAJINKPMORJF-UHFFFAOYSA-N
- Appearance
- White, odorless crystalline powder with a slightly bitter taste.
- Solubility
- Soluble in boiling water and in 1 N sodium hydroxide, and freely soluble in alcohol.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Sold in several physical grades: powder, fine powder, dense crystalline and directly compressible. State the grade, and the limit you need for 4-aminophenol.
On the US market
- Approved ANDAs
- 17 with a marketed product
- Approved forms and strengths
- Injection 500 mg/50 mL, 650 mg/65 mL, 1 g/100 mL
- Extended-release tablet 650 mg
- Suppository 80 mg, 120 mg, 325 mg, 650 mg
Most acetaminophen products are sold under the OTC monograph and do not appear in Drugs@FDA, so the figures here cover only products approved by application. Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com